Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marek Ancukiewicz

Showing results (71-80 of 81) with videos related to

Pageof 9
Sort By:
Gynecologic Oncology|August 28, 2021
Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancerDavid M O'Malley, Ana Oaknin, Bradley J Monk, et al.
The Oncologist|December 20, 2011
Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotypingDarrell R Borger, Kenneth K Tanabe, Kenneth C Fan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2009
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II studyChristopher G Willett, Dan G Duda, Emmanuelle di Tomaso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2016
PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in ObesityJoao Incio, Josh Tam, Nuh N Rahbari, et al.
Cancer Cell|January 16, 2007
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patientsTracy T Batchelor, A Gregory Sorensen, Emmanuelle di Tomaso, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2009
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II studyAndrew X Zhu, Dushyant V Sahani, Dan G Duda, et al.
Science Translational Medicine|March 16, 2018
Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2Joao Incio, Jennifer A Ligibel, Daniel T McManus, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 6, 2013
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiationTracy T Batchelor, Elizabeth R Gerstner, Kyrre E Emblem, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 26, 2015
A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma PatientsEudocia Q Lee, Thomas J Kaley, Dan G Duda, et al.
International Journal of Radiation Oncology, Biology, Physics|May 29, 2014
A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinomaTheodore S Hong, David P Ryan, Darrell R Borger, et al.
Pageof 9

Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
Gynecologic Oncology|August 28, 2021
Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancerDavid M O'Malley, Ana Oaknin, Bradley J Monk, et al.
The Oncologist|December 20, 2011
Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotypingDarrell R Borger, Kenneth K Tanabe, Kenneth C Fan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2009
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II studyChristopher G Willett, Dan G Duda, Emmanuelle di Tomaso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2016
PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in ObesityJoao Incio, Josh Tam, Nuh N Rahbari, et al.
Cancer Cell|January 16, 2007
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patientsTracy T Batchelor, A Gregory Sorensen, Emmanuelle di Tomaso, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2009
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II studyAndrew X Zhu, Dushyant V Sahani, Dan G Duda, et al.
Science Translational Medicine|March 16, 2018
Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2Joao Incio, Jennifer A Ligibel, Daniel T McManus, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 6, 2013
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiationTracy T Batchelor, Elizabeth R Gerstner, Kyrre E Emblem, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 26, 2015
A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma PatientsEudocia Q Lee, Thomas J Kaley, Dan G Duda, et al.
International Journal of Radiation Oncology, Biology, Physics|May 29, 2014
A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinomaTheodore S Hong, David P Ryan, Darrell R Borger, et al.
Pageof 9